

# Global Duchenne Muscular Dystrophy Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

<https://marketpublishers.com/r/GCE6AE9815B3EN.html>

Date: January 2023

Pages: 103

Price: US\$ 3,480.00 (Single User License)

ID: GCE6AE9815B3EN

## Abstracts

According to our (Global Info Research) latest study, the global Duchenne Muscular Dystrophy Drugs market size was valued at USD 1041.1 million in 2022 and is forecast to a readjusted size of USD 7464.7 million by 2029 with a CAGR of 32.5% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Duchenne Muscular Dystrophy Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Duchenne Muscular Dystrophy Drugs market size and forecasts, in consumption value (\$ Million), 2018-2029

Global Duchenne Muscular Dystrophy Drugs market size and forecasts by region and country, in consumption value (\$ Million), 2018-2029

Global Duchenne Muscular Dystrophy Drugs market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2018-2029

Global Duchenne Muscular Dystrophy Drugs market shares of main players, in revenue (\$ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Duchenne Muscular Dystrophy Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Duchenne Muscular Dystrophy Drugs market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Biogen, Roche, Daiichi Sankyo, Pfizer and Cumberland Pharmaceuticals, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Duchenne Muscular Dystrophy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Molecular-based Therapies

Steroid Therapy

Other

Market segment by Application

Hospitals

Clinics

Others

Market segment by players, this report covers

Biogen

Roche

Daiichi Sankyo

Pfizer

Cumberland Pharmaceuticals

Santhera Pharmaceuticals

Taiho Pharmaceutical

Teijin Pharma

Akashi Therapeutics

Sarepta Therapeutics

BioMarin

Fibrogen Inc

Nobelpharma Co. Ltd

Eloxx Pharmaceuticals

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)

South America (Brazil, Argentina and Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Duchenne Muscular Dystrophy Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Duchenne Muscular Dystrophy Drugs, with revenue, gross margin and global market share of Duchenne Muscular Dystrophy Drugs from 2018 to 2023.

Chapter 3, the Duchenne Muscular Dystrophy Drugs competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023. and Duchenne Muscular Dystrophy Drugs market forecast, by regions, type and application, with consumption value, from 2024 to 2029.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War

Chapter 12, the key raw materials and key suppliers, and industry chain of Duchenne Muscular Dystrophy Drugs.

Chapter 13, to describe Duchenne Muscular Dystrophy Drugs research findings and

conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope of Duchenne Muscular Dystrophy Drugs

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Duchenne Muscular Dystrophy Drugs by Type

1.3.1 Overview: Global Duchenne Muscular Dystrophy Drugs Market Size by Type: 2018 Versus 2022 Versus 2029

1.3.2 Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Type in 2022

1.3.3 Molecular-based Therapies

1.3.4 Steroid Therapy

1.3.5 Other

1.4 Global Duchenne Muscular Dystrophy Drugs Market by Application

1.4.1 Overview: Global Duchenne Muscular Dystrophy Drugs Market Size by Application: 2018 Versus 2022 Versus 2029

1.4.2 Hospitals

1.4.3 Clinics

1.4.4 Others

1.5 Global Duchenne Muscular Dystrophy Drugs Market Size & Forecast

1.6 Global Duchenne Muscular Dystrophy Drugs Market Size and Forecast by Region

1.6.1 Global Duchenne Muscular Dystrophy Drugs Market Size by Region: 2018 VS 2022 VS 2029

1.6.2 Global Duchenne Muscular Dystrophy Drugs Market Size by Region, (2018-2029)

1.6.3 North America Duchenne Muscular Dystrophy Drugs Market Size and Prospect (2018-2029)

1.6.4 Europe Duchenne Muscular Dystrophy Drugs Market Size and Prospect (2018-2029)

1.6.5 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size and Prospect (2018-2029)

1.6.6 South America Duchenne Muscular Dystrophy Drugs Market Size and Prospect (2018-2029)

1.6.7 Middle East and Africa Duchenne Muscular Dystrophy Drugs Market Size and Prospect (2018-2029)

### 2 COMPANY PROFILES

## 2.1 Biogen

### 2.1.1 Biogen Details

### 2.1.2 Biogen Major Business

### 2.1.3 Biogen Duchenne Muscular Dystrophy Drugs Product and Solutions

### 2.1.4 Biogen Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

### 2.1.5 Biogen Recent Developments and Future Plans

## 2.2 Roche

### 2.2.1 Roche Details

### 2.2.2 Roche Major Business

### 2.2.3 Roche Duchenne Muscular Dystrophy Drugs Product and Solutions

### 2.2.4 Roche Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

### 2.2.5 Roche Recent Developments and Future Plans

## 2.3 Daiichi Sankyo

### 2.3.1 Daiichi Sankyo Details

### 2.3.2 Daiichi Sankyo Major Business

### 2.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product and Solutions

### 2.3.4 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

### 2.3.5 Daiichi Sankyo Recent Developments and Future Plans

## 2.4 Pfizer

### 2.4.1 Pfizer Details

### 2.4.2 Pfizer Major Business

### 2.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Product and Solutions

### 2.4.4 Pfizer Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

### 2.4.5 Pfizer Recent Developments and Future Plans

## 2.5 Cumberland Pharmaceuticals

### 2.5.1 Cumberland Pharmaceuticals Details

### 2.5.2 Cumberland Pharmaceuticals Major Business

### 2.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions

### 2.5.4 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

### 2.5.5 Cumberland Pharmaceuticals Recent Developments and Future Plans

## 2.6 Santhera Pharmaceuticals

### 2.6.1 Santhera Pharmaceuticals Details

### 2.6.2 Santhera Pharmaceuticals Major Business

2.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions

2.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

2.6.5 Santhera Pharmaceuticals Recent Developments and Future Plans

2.7 Taiho Pharmaceutical

2.7.1 Taiho Pharmaceutical Details

2.7.2 Taiho Pharmaceutical Major Business

2.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product and Solutions

2.7.4 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

2.7.5 Taiho Pharmaceutical Recent Developments and Future Plans

2.8 Teijin Pharma

2.8.1 Teijin Pharma Details

2.8.2 Teijin Pharma Major Business

2.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Product and Solutions

2.8.4 Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

2.8.5 Teijin Pharma Recent Developments and Future Plans

2.9 Akashi Therapeutics

2.9.1 Akashi Therapeutics Details

2.9.2 Akashi Therapeutics Major Business

2.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product and Solutions

2.9.4 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

2.9.5 Akashi Therapeutics Recent Developments and Future Plans

2.10 Sarepta Therapeutics

2.10.1 Sarepta Therapeutics Details

2.10.2 Sarepta Therapeutics Major Business

2.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product and Solutions

2.10.4 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)

2.10.5 Sarepta Therapeutics Recent Developments and Future Plans

2.11 BioMarin

2.11.1 BioMarin Details

2.11.2 BioMarin Major Business



- 2.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Product and Solutions
- 2.11.4 BioMarin Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)
- 2.11.5 BioMarin Recent Developments and Future Plans
- 2.12 Fibrogen Inc
  - 2.12.1 Fibrogen Inc Details
  - 2.12.2 Fibrogen Inc Major Business
  - 2.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product and Solutions
  - 2.12.4 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)
  - 2.12.5 Fibrogen Inc Recent Developments and Future Plans
- 2.13 Nobelpharma Co. Ltd
  - 2.13.1 Nobelpharma Co. Ltd Details
  - 2.13.2 Nobelpharma Co. Ltd Major Business
  - 2.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product and Solutions
  - 2.13.4 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)
  - 2.13.5 Nobelpharma Co. Ltd Recent Developments and Future Plans
- 2.14 Eloxx Pharmaceuticals
  - 2.14.1 Eloxx Pharmaceuticals Details
  - 2.14.2 Eloxx Pharmaceuticals Major Business
  - 2.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions
  - 2.14.4 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2018-2023)
  - 2.14.5 Eloxx Pharmaceuticals Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

- 3.1 Global Duchenne Muscular Dystrophy Drugs Revenue and Share by Players (2018-2023)
- 3.2 Market Share Analysis (2022)
  - 3.2.1 Market Share of Duchenne Muscular Dystrophy Drugs by Company Revenue
  - 3.2.2 Top 3 Duchenne Muscular Dystrophy Drugs Players Market Share in 2022
  - 3.2.3 Top 6 Duchenne Muscular Dystrophy Drugs Players Market Share in 2022
- 3.3 Duchenne Muscular Dystrophy Drugs Market: Overall Company Footprint Analysis
  - 3.3.1 Duchenne Muscular Dystrophy Drugs Market: Region Footprint
  - 3.3.2 Duchenne Muscular Dystrophy Drugs Market: Company Product Type Footprint

- 3.3.3 Duchenne Muscular Dystrophy Drugs Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

- 4.1 Global Duchenne Muscular Dystrophy Drugs Consumption Value and Market Share by Type (2018-2023)
- 4.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Type (2024-2029)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

- 5.1 Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Application (2018-2023)
- 5.2 Global Duchenne Muscular Dystrophy Drugs Market Forecast by Application (2024-2029)

## **6 NORTH AMERICA**

- 6.1 North America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2029)
- 6.2 North America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2029)
- 6.3 North America Duchenne Muscular Dystrophy Drugs Market Size by Country
  - 6.3.1 North America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2029)
  - 6.3.2 United States Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)
  - 6.3.3 Canada Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)
  - 6.3.4 Mexico Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

## **7 EUROPE**

- 7.1 Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2029)
- 7.2 Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Application

(2018-2029)

### 7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Country

7.3.1 Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Country  
(2018-2029)

7.3.2 Germany Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

7.3.3 France Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

7.3.4 United Kingdom Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

7.3.5 Russia Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

7.3.6 Italy Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

## **8 ASIA-PACIFIC**

8.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Type  
(2018-2029)

8.2 Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by  
Application (2018-2029)

### 8.3 Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Size by Region

8.3.1 Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Region  
(2018-2029)

8.3.2 China Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

8.3.3 Japan Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

8.3.4 South Korea Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

8.3.5 India Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

8.3.6 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

8.3.7 Australia Duchenne Muscular Dystrophy Drugs Market Size and Forecast  
(2018-2029)

## **9 SOUTH AMERICA**

9.1 South America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2029)

9.2 South America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2029)

9.3 South America Duchenne Muscular Dystrophy Drugs Market Size by Country

9.3.1 South America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2029)

9.3.2 Brazil Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

9.3.3 Argentina Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

## **10 MIDDLE EAST & AFRICA**

10.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2029)

10.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2029)

10.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Country

10.3.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2029)

10.3.2 Turkey Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

10.3.3 Saudi Arabia Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

10.3.4 UAE Duchenne Muscular Dystrophy Drugs Market Size and Forecast (2018-2029)

## **11 MARKET DYNAMICS**

11.1 Duchenne Muscular Dystrophy Drugs Market Drivers

11.2 Duchenne Muscular Dystrophy Drugs Market Restraints

11.3 Duchenne Muscular Dystrophy Drugs Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## 11.5 Influence of COVID-19 and Russia-Ukraine War

### 11.5.1 Influence of COVID-19

### 11.5.2 Influence of Russia-Ukraine War

## **12 INDUSTRY CHAIN ANALYSIS**

### 12.1 Duchenne Muscular Dystrophy Drugs Industry Chain

### 12.2 Duchenne Muscular Dystrophy Drugs Upstream Analysis

### 12.3 Duchenne Muscular Dystrophy Drugs Midstream Analysis

### 12.4 Duchenne Muscular Dystrophy Drugs Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

### 14.1 Methodology

### 14.2 Research Process and Data Source

### 14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029

Table 2. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Application, (USD Million), 2018 & 2022 & 2029

Table 3. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)

Table 4. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)

Table 5. Biogen Company Information, Head Office, and Major Competitors

Table 6. Biogen Major Business

Table 7. Biogen Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 8. Biogen Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 9. Biogen Recent Developments and Future Plans

Table 10. Roche Company Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 13. Roche Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 14. Roche Recent Developments and Future Plans

Table 15. Daiichi Sankyo Company Information, Head Office, and Major Competitors

Table 16. Daiichi Sankyo Major Business

Table 17. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 18. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 19. Daiichi Sankyo Recent Developments and Future Plans

Table 20. Pfizer Company Information, Head Office, and Major Competitors

Table 21. Pfizer Major Business

Table 22. Pfizer Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 23. Pfizer Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 24. Pfizer Recent Developments and Future Plans

Table 25. Cumberland Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 26. Cumberland Pharmaceuticals Major Business

- Table 27. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions
- Table 28. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 29. Cumberland Pharmaceuticals Recent Developments and Future Plans
- Table 30. Santhera Pharmaceuticals Company Information, Head Office, and Major Competitors
- Table 31. Santhera Pharmaceuticals Major Business
- Table 32. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions
- Table 33. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 34. Santhera Pharmaceuticals Recent Developments and Future Plans
- Table 35. Taiho Pharmaceutical Company Information, Head Office, and Major Competitors
- Table 36. Taiho Pharmaceutical Major Business
- Table 37. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product and Solutions
- Table 38. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 39. Taiho Pharmaceutical Recent Developments and Future Plans
- Table 40. Teijin Pharma Company Information, Head Office, and Major Competitors
- Table 41. Teijin Pharma Major Business
- Table 42. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product and Solutions
- Table 43. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 44. Teijin Pharma Recent Developments and Future Plans
- Table 45. Akashi Therapeutics Company Information, Head Office, and Major Competitors
- Table 46. Akashi Therapeutics Major Business
- Table 47. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product and Solutions
- Table 48. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)
- Table 49. Akashi Therapeutics Recent Developments and Future Plans
- Table 50. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
- Table 51. Sarepta Therapeutics Major Business
- Table 52. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product and

## Solutions

Table 53. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 54. Sarepta Therapeutics Recent Developments and Future Plans

Table 55. BioMarin Company Information, Head Office, and Major Competitors

Table 56. BioMarin Major Business

Table 57. BioMarin Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 58. BioMarin Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 59. BioMarin Recent Developments and Future Plans

Table 60. Fibrogen Inc Company Information, Head Office, and Major Competitors

Table 61. Fibrogen Inc Major Business

Table 62. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 63. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 64. Fibrogen Inc Recent Developments and Future Plans

Table 65. Nobelpharma Co. Ltd Company Information, Head Office, and Major Competitors

Table 66. Nobelpharma Co. Ltd Major Business

Table 67. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 68. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 69. Nobelpharma Co. Ltd Recent Developments and Future Plans

Table 70. Eloxx Pharmaceuticals Company Information, Head Office, and Major Competitors

Table 71. Eloxx Pharmaceuticals Major Business

Table 72. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product and Solutions

Table 73. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue (USD Million), Gross Margin and Market Share (2018-2023)

Table 74. Eloxx Pharmaceuticals Recent Developments and Future Plans

Table 75. Global Duchenne Muscular Dystrophy Drugs Revenue (USD Million) by Players (2018-2023)

Table 76. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Players (2018-2023)

Table 77. Breakdown of Duchenne Muscular Dystrophy Drugs by Company Type (Tier 1, Tier 2, and Tier 3)

Table 78. Market Position of Players in Duchenne Muscular Dystrophy Drugs, (Tier 1,



Tier 2, and Tier 3), Based on Revenue in 2022

Table 79. Head Office of Key Duchenne Muscular Dystrophy Drugs Players

Table 80. Duchenne Muscular Dystrophy Drugs Market: Company Product Type Footprint

Table 81. Duchenne Muscular Dystrophy Drugs Market: Company Product Application Footprint

Table 82. Duchenne Muscular Dystrophy Drugs New Market Entrants and Barriers to Market Entry

Table 83. Duchenne Muscular Dystrophy Drugs Mergers, Acquisition, Agreements, and Collaborations

Table 84. Global Duchenne Muscular Dystrophy Drugs Consumption Value (USD Million) by Type (2018-2023)

Table 85. Global Duchenne Muscular Dystrophy Drugs Consumption Value Share by Type (2018-2023)

Table 86. Global Duchenne Muscular Dystrophy Drugs Consumption Value Forecast by Type (2024-2029)

Table 87. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023)

Table 88. Global Duchenne Muscular Dystrophy Drugs Consumption Value Forecast by Application (2024-2029)

Table 89. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)

Table 90. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)

Table 91. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 92. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)

Table 93. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 94. North America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 95. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)

Table 96. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)

Table 97. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 98. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by

Application (2024-2029) & (USD Million)

Table 99. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 100. Europe Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 101. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)

Table 102. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)

Table 103. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 104. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)

Table 105. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Region (2018-2023) & (USD Million)

Table 106. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value by Region (2024-2029) & (USD Million)

Table 107. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)

Table 108. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)

Table 109. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 110. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)

Table 111. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 112. South America Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 113. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2018-2023) & (USD Million)

Table 114. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Type (2024-2029) & (USD Million)

Table 115. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2018-2023) & (USD Million)

Table 116. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Application (2024-2029) & (USD Million)

Table 117. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2018-2023) & (USD Million)

Table 118. Middle East & Africa Duchenne Muscular Dystrophy Drugs Consumption Value by Country (2024-2029) & (USD Million)

Table 119. Duchenne Muscular Dystrophy Drugs Raw Material

Table 120. Key Suppliers of Duchenne Muscular Dystrophy Drugs Raw Materials

## List Of Figures

### LIST OF FIGURES

- Figure 1. Duchenne Muscular Dystrophy Drugs Picture
- Figure 2. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 3. Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Type in 2022
- Figure 4. Molecular-based Therapies
- Figure 5. Steroid Therapy
- Figure 6. Other
- Figure 7. Global Duchenne Muscular Dystrophy Drugs Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
- Figure 8. Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Application in 2022
- Figure 9. Hospitals Picture
- Figure 10. Clinics Picture
- Figure 11. Others Picture
- Figure 12. Global Duchenne Muscular Dystrophy Drugs Consumption Value, (USD Million): 2018 & 2022 & 2029
- Figure 13. Global Duchenne Muscular Dystrophy Drugs Consumption Value and Forecast (2018-2029) & (USD Million)
- Figure 14. Global Market Duchenne Muscular Dystrophy Drugs Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
- Figure 15. Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Region (2018-2029)
- Figure 16. Global Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Region in 2022
- Figure 17. North America Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)
- Figure 18. Europe Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)
- Figure 19. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)
- Figure 20. South America Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)
- Figure 21. Middle East and Africa Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 22. Global Duchenne Muscular Dystrophy Drugs Revenue Share by Players in 2022

Figure 23. Duchenne Muscular Dystrophy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022

Figure 24. Global Top 3 Players Duchenne Muscular Dystrophy Drugs Market Share in 2022

Figure 25. Global Top 6 Players Duchenne Muscular Dystrophy Drugs Market Share in 2022

Figure 26. Global Duchenne Muscular Dystrophy Drugs Consumption Value Share by Type (2018-2023)

Figure 27. Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Type (2024-2029)

Figure 28. Global Duchenne Muscular Dystrophy Drugs Consumption Value Share by Application (2018-2023)

Figure 29. Global Duchenne Muscular Dystrophy Drugs Market Share Forecast by Application (2024-2029)

Figure 30. North America Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Type (2018-2029)

Figure 31. North America Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Application (2018-2029)

Figure 32. North America Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Country (2018-2029)

Figure 33. United States Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 34. Canada Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 35. Mexico Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 36. Europe Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Type (2018-2029)

Figure 37. Europe Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Application (2018-2029)

Figure 38. Europe Duchenne Muscular Dystrophy Drugs Consumption Value Market Share by Country (2018-2029)

Figure 39. Germany Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 40. France Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 41. United Kingdom Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 42. Russia Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 43. Italy Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029)

& (USD Million)

Figure 44. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Type (2018-2029)

Figure 45. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Application (2018-2029)

Figure 46. Asia-Pacific Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Region (2018-2029)

Figure 47. China Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 48. Japan Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 49. South Korea Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 50. India Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029)

& (USD Million)

Figure 51. Southeast Asia Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 52. Australia Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 53. South America Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Type (2018-2029)

Figure 54. South America Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Application (2018-2029)

Figure 55. South America Duchenne Muscular Dystrophy Drugs Consumption Value

Market Share by Country (2018-2029)

Figure 56. Brazil Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029)

& (USD Million)

Figure 57. Argentina Duchenne Muscular Dystrophy Drugs Consumption Value

(2018-2029) & (USD Million)

Figure 58. Middle East and Africa Duchenne Muscular Dystrophy Drugs Consumption

Value Market Share by Type (2018-2029)

Figure 59. Middle East and Africa Duchenne Muscular Dystrophy Drugs Consumption

Value Market Share by Application (2018-2029)

Figure 60. Middle East and Africa Duchenne Muscular Dystrophy Drugs Consumption

Value Market Share by Country (2018-2029)

Figure 61. Turkey Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 62. Saudi Arabia Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 63. UAE Duchenne Muscular Dystrophy Drugs Consumption Value (2018-2029) & (USD Million)

Figure 64. Duchenne Muscular Dystrophy Drugs Market Drivers

Figure 65. Duchenne Muscular Dystrophy Drugs Market Restraints

Figure 66. Duchenne Muscular Dystrophy Drugs Market Trends

Figure 67. Porters Five Forces Analysis

Figure 68. Manufacturing Cost Structure Analysis of Duchenne Muscular Dystrophy Drugs in 2022

Figure 69. Manufacturing Process Analysis of Duchenne Muscular Dystrophy Drugs

Figure 70. Duchenne Muscular Dystrophy Drugs Industrial Chain

Figure 71. Methodology

Figure 72. Research Process and Data Source

## I would like to order

Product name: Global Duchenne Muscular Dystrophy Drugs Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Product link: <https://marketpublishers.com/r/GCE6AE9815B3EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GCE6AE9815B3EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



